(Abst.) Severe disease activity in a patient w/MS after daclizumab discontinuation on: December 17, 2018, 10:02:37 am #1 From PubMed, December 17, 2018--"Severe disease activity in a patient with multiple sclerosis after daclizumab discontinuation": Severe disease activity in a patient with multiple sclerosis after daclizumab discontinuation - PubMed Daclizumab, a MS treatment targeting IL2-receptor, has been recently withdrawn following reports of immune-mediated encephalitis. We report the case of a 39-years-old woman treated with daclizumab ... PubMed · ncbi.nlm.nih.gov Daclizumab (Zinbryta) has been taken off the market. For some background, here is a thread from a few months ago about it:https://msspeaks.createaforum.com/treatments/zinbryta-being-pulled-from-market-due-to-safety-concerns/msg2172/#msg2172 Logged MS Speaks--online for 20 yearsSPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010. Glatopa (glatiramer acetate 40mg 3 times/week) 12/16/20 - 3/16/24.
